China, a global hotspot for liver and digestive system diseases, has emerged as an attractive target market for developers of genomic liver and colon cancer screening tests, with the potential to generate billions of dollars of annual revenue. California-based Helio – formerly the Laboratory for Advanced Medicine – will soon apply for approval in China […]

A cancer-fighting concept from the inventor of the first cancer vaccine is nearing prime time, and its biotech developer has received a significant new infusion of cash to get it there. Bolt Biotherapeutics announced a $93.5 million Series C round led by Sofinnova Investments and joined by more than 9 others, including Pfizer Ventures and […]

Ten months ago Randy Schatzman was appointed CEO of cancer drug developer Bolt Biotherapeutics, and tasked with getting its first drug candidate into the clinic, building out its C-suite, and raising more money. On Wednesday Schatzman checked the last box on that priority list, closing a $93.5 million Series C financing round from a group […]